SGN 30

Drug Profile

SGN 30

Alternative Names: AC 10 mAb; Anti-CD30 antibody; SGN-30

Latest Information Update: 17 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cutaneous T cell lymphoma; Hodgkin's disease

Most Recent Events

  • 13 Nov 2006 Interim results from a phase II clinical trial in patients with cutaneous anaplastic large cell lymphoma have been added to the Cancer therapeutic trials sections
  • 16 May 2005 Phase-II clinical trials in Cutaneous T-cell lymphoma (ALCL) in Europe (unspecified route)
  • 16 May 2005 Data presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO-2005) have been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top